Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

[1]  S. Kasper.  Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia , 1998, International clinical psychopharmacology.

[2]  A. Malhotra,et al.  Dopamine D2 receptor density and personal detachment in healthy subjects. , 1998, The American journal of psychiatry.

[3]  M. Nader,et al.  Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography , 1998, Synapse.

[4]  C. Nemeroff,et al.  Dosing the antipsychotic medication olanzapine. , 1997, The Journal of clinical psychiatry.

[5]  G. Simpson,et al.  Extrapyramidal symptoms in patients treated with risperidone. , 1997, Journal of clinical psychopharmacology.

[6]  I. Kusumi,et al.  Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. , 1997, European journal of pharmacology.

[7]  J. Petter Gustavsson,et al.  D2 dopamine receptors and personality traits , 1997, Nature.

[8]  J. Lieberman,et al.  Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia , 1996 .

[9]  C. Stone,et al.  Further evidence of a dose-response threshold for haloperidol in psychosis. , 1995, The American journal of psychiatry.

[10]  J. Peuskens.  Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol , 1995, British Journal of Psychiatry.

[11]  R. Murray,et al.  D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients , 1994, British Journal of Psychiatry.

[12]  J S Fowler,et al.  Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. See.  Assessment of Striatal Extracellular Dopamine and Dopamine Metabolites by Microdialysis in Haloperidol-Treated Rats Exhibiting Oral Dyskinesia , 1993, Neuropsychopharmacology.

[14]  W. Glazer,et al.  Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. , 1993, Archives of general psychiatry.

[15]  J. Doucette,et al.  Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. , 1993, The Journal of clinical psychiatry.

[16]  R. Yassa,et al.  Tardive dyskinesia in elderly psychiatric patients: a 5-year study. , 1992, The American journal of psychiatry.

[17]  P. Kalivas,et al.  In vivo assessment of release and metabolism of dopamine in the ventrolateral striatum of awake rats following administration of dopamine D1 and D2 receptor agonists and antagonists , 1991, Neuropharmacology.

[18]  S. Steingard,et al.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. , 1991, Archives of general psychiatry.

[19]  J. Waddington,et al.  Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia , 1990, Psychological Medicine.

[20]  G McKay,et al.  Intersubject Variation in the Pharmacokinetics of Haloperidol and Reduced Haloperidol , 1989, Journal of clinical psychopharmacology.

[21]  C. Prasad,et al.  Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density. , 1989, Biochemical and biophysical research communications.

[22]  P. Seeman.  Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. , 1988, Journal of clinical psychopharmacology.

[23]  G. Chouinard,et al.  A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. , 1988, Journal of clinical psychopharmacology.

[24]  J. Baron,et al.  In Vivo Assay for Neuroleptic Receptor Binding in the Striatum , 1987, British Journal of Psychiatry.

[25]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[26]  U. Bondesson,et al.  Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration , 1986, Pharmacology Biochemistry and Behavior.

[27]  C. Goetz,et al.  The effect of antimuscarinic agents on haloperidol induced behavioral hypersensitivity. , 1986, European journal of pharmacology.

[28]  C. Marsden,et al.  Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors. , 1983, Biochemical pharmacology.

[29]  C. Marsden,et al.  The effect of chronic neuroleptic administration on cerebral dopamine receptor function. , 1983, Life sciences.

[30]  J. Waddington,et al.  Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. , 1983, Science.

[31]  J. Kane,et al.  A Prospective Study of Tardive Dyskinesia Development: Preliminary Results , 1982, Journal of clinical psychopharmacology.

[32]  C. Marsden,et al.  Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months , 1979, Nature.

[33]  P. Seeman,et al.  Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains , 1978, Nature.

[34]  P. Seeman,et al.  Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. , 1977, Life sciences.

[35]  S. Snyder,et al.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. , 1977, Science.

[36]  R. Baldessarini,et al.  Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. , 1974, Neuropharmacology.

[37]  G. Simpson,et al.  A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.

[38]  M. Tohen,et al.  Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. , 1997, Archives of general psychiatry.

[39]  H. Meltzer,et al.  Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. , 1991, The Journal of pharmacology and experimental therapeutics.

[40]  Martin H. Teicher,et al.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. , 1988, Archives of general psychiatry.

[41]  C. Goetz,et al.  Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation. , 1988, Life sciences.

[42]  Philip Seeman,et al.  Human brain dopamine receptors in children and aging adults , 1987, Synapse.